Home GPCR & G Protein CCK receptor inhibitor Rebamipide

research use only

Rebamipide CCK receptor inhibitor

Cat.No.S2032

Rebamipide (OPC-12759,Proamipide) is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 μM.
Rebamipide CCK receptor inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 370.79

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S203201 DMSO]74 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.97%
99.97

Chemical Information, Storage & Stability

Molecular Weight 370.79 Formula

C19H15ClN2O4

 Storage (From the date of receipt)
CAS No. 90098-04-7 Download SDF Storage of Stock Solutions

Synonyms OPC-12759,Proamipide Smiles C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl

Solubility

In vitro
Batch:

DMSO : 74 mg/mL (199.57 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04150172 Completed
Healthy Volunteers
Korea Otsuka Pharmaceutical Co. Ltd.
 April 22 2019 Phase 1
NCT02106130 Completed
Healthy
IlDong Pharmaceutical Co Ltd
 May 2013 Phase 1
NCT01167101 Completed
Stomach Ulcer
Kangdong Sacred Heart Hospital
 May 2009 Not Applicable
NCT00997789 Completed
Therapeutic Equivalency|Pharmacogenetics
Chonnam National University Hospital|Institute of Bioequivalence and Bridging Study College of Pharmacy CNU
 March 2008 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.